Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma

Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma

This article contains data on clinical endpoints (Peak Flow Expiratory Rate, fractional exhaled nitric oxide and total IgE serum levels) and plasma pharmacokinetic parameters concerning the use of the oral CRTh2 antagonist QAW039 (fevipiprant) in mild to moderate asthma patients. Information on expe...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Veit J. Erpenbeck, Todor A. Popov, David Miller, Steven F. Weinstein, Sheldon Spector, Baldur Magnusson, Wande Osuntokun, Paul Goldsmith, Markus Weiss, Jutta Beier
Formatua: Artikulua
Hizkuntza:English
Argitaratua: Elsevier 2016-12-01
Saila:Data in Brief
Sarrera elektronikoa:http://www.sciencedirect.com/science/article/pii/S2352340916305406

Internet

http://www.sciencedirect.com/science/article/pii/S2352340916305406

Antzeko izenburuak